August 30, 2010
Positive results from the SHIFT trial were published in the Lancet online, August 29, 2010. With more than 6500 patients in 37 countries it is the largest heart failure trial published to date. Contract research Organization A+ Science managed the coordination of sites from start up to close-out in 6 European countries.
The SHIFT trial evaluated Ivabradine, an If inhibitor already indicated for the treatment of coronary artery disease. The results showed a significantly reduced risk of cardiovascular death and hospital admissions when added to standard treatments in patients with chronic heart failure and elevated heart rates.
Return to news list